CAS,endPoint
134-62-3,
,TOX21_p53_BLA_p3_ratio
,TOX21_p53_BLA_p2_viability
82657-04-3,BSK_3C_Vis_down
82657-04-3,TOX21_NFkB_BLA_agonist_ch1
82657-04-3,NVS_NR_hPR
120068-37-3,NVS_NR_hCAR_Antagonist
60-51-5,NVS_NR_bER
13194-48-4,NCCT_QuantiLum_inhib_dn
161050-58-4,ATG_Myb_CIS_up
173584-44-6,ATG_HSE_CIS_up
30560-19-1,BSK_3C_SRB_up
30560-19-1,ATG_M_19_TRANS_dn
61949-77-7,ATG_CMV_CIS_dn
